Detailed data from the Phase 1 first-in-human study of BRB-002 will be presented at the American College of Cardiology Scientific Session in March 2025. A Phase 2 proof-of-concept trial of BRB-002 in ...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...